Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb
04. Juni 2020 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
PharmaCyte Biotech’s Pancreatic Cancer Therapy Passes Critical FDA-Required Tests as Countdown to IND Submission Begins
27. Januar 2020 09:00 ET
|
PharmaCyte Biotech
NEW YORK, NY, Jan. 27, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) announced that its clinical trial product, which will be employed during the company’s upcoming Phase 2b clinical...
Celgene Rescinds Agreement to Compensate Cancer Patients Days Before Christmas
08. Januar 2020 13:36 ET
|
Hausfeld
WASHINGTON, Jan. 08, 2020 (GLOBE NEWSWIRE) -- On December 23, 2019, Celgene backed out of a settlement in which it had agreed to pay $55 million to end payors (consumers, insurers, union health and...
Jounce Therapeutics Reports Second Quarter 2019 Financial Results
07. August 2019 06:30 ET
|
Jounce Therapeutics, Inc.
- Initiated Phase 2 EMERGE trial of vopratelimab - - Completed enrollment of Phase 1 trial of JTX-4014 - - Updated strategic collaboration and established new licensing agreement with...
Hausfeld Announces $55 Million Settlement in Antitrust Class Action Against Celgene
24. Juli 2019 11:19 ET
|
Hausfeld
WASHINGTON, July 24, 2019 (GLOBE NEWSWIRE) -- Hausfeld, a global claimants’ law firm dedicated to handling complex litigation, announced today that it has reached a $55 million settlement with...
Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation
23. Juli 2019 16:00 ET
|
Jounce Therapeutics, Inc.
- Celgene licenses JTX-8064, resulting in $50.0 million upfront payment to Jounce - - Jounce retains full worldwide rights to vopratelimab, JTX‑4014 and all discovery programs - - Company to host...
VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Development and Medical Affairs
17. April 2019 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., April 17, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
PharmaCyte Biotech Nearing Major Milestone—An Open IND with the FDA
04. Februar 2019 09:20 ET
|
PharmaCyte Biotech
NEW YORK, NY, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Clinical stage biotechnology company PharmaCyte Biotech (OTCQB: PMCB) is now closer than ever to reaching what would be a monumental milestone in the...
MaRS Innovation’s Triphase Accelerator Announces New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy
29. Januar 2019 08:00 ET
|
MaRS Innovation
Toronto, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator, a Toronto-based drug development company, has entered into a new strategic partnership with Celgene Corporation. The focus of the...
World-Renowned Oncologist Bullish on Potential of PharmaCyte’s Technology, Clinical Trial in Pancreatic Cancer
23. Januar 2019 09:25 ET
|
PharmaCyte Biotech
NEW YORK, NY, Jan. 23, 2019 (GLOBE NEWSWIRE) -- With PharmaCyte Biotech, Inc.’s (OTCQB: PMCB) naming of Medpace, Inc., a global full-service clinical contract research organization (CRO) to conduct...